

DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED											
Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009											
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER, 2008 (Rupees in Lakhs)											
Sr. No.	PARTICULARS	STANDALONE					CONSOLIDATED				
		3 Months ended 31-12-2008	Corresponding 3 months ended in the previous year 31-12-2007	Year to Date figures for current Period ended 31-12-2008	Year to date figures for the previous period ended 31-12-2007	Previous accounting year ended 31-03-2008	3 Months ended 31-12-2008	Corresponding 3 months ended in the previous year 31-12-2007	Year to Date figures for current Period ended 31-12-2008	Year to date figures for the previous period ended 31-12-2007	Previous accounting year ended 31-03-2008
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>a) Net Sales/Income From Operations</b>	<b>10,950.71</b>	<b>10,014.82</b>	<b>31,115.93</b>	<b>25,614.93</b>	<b>35,920.03</b>	<b>28,196.15</b>	<b>20,657.20</b>	<b>76,985.37</b>	<b>56,112.70</b>	<b>80,307.62</b>
	b) Other Operating Income	17.57	77.29	48.29	92.88	99.97	19.09	61.46	410.34	117.53	135.90
	c) Income from Associates	-	-	-	-	-	(0.01)	-	2.32	2.32	0.56
	<b>Total Income (a+b+c)</b>	<b>10,968.28</b>	<b>10,092.12</b>	<b>31,164.22</b>	<b>25,707.82</b>	<b>36,020.00</b>	<b>28,215.23</b>	<b>20,718.66</b>	<b>77,398.03</b>	<b>56,232.55</b>	<b>80,444.08</b>
2	Expenditure										
	a) (Increase)/Decrease in Stock in trade and work in progress	281.36	(155.80)	188.21	(912.80)	(1,557.20)	233.25	(188.04)	70.74	(1,722.27)	(2,159.12)
	b) Consumption of Raw Materials	3,012.82	2,576.60	10,548.60	8,955.42	12,543.56	6,204.46	4,319.13	19,713.45	14,964.86	24,027.90
	c) Purchase of traded goods	2,114.59	2,729.37	2,199.39	5,139.79	7,376.24	2,902.76	3,577.66	4,015.90	6,970.58	7,450.46
	d) Employee Cost	862.21	753.89	2,505.47	2,074.56	2,840.29	6,990.46	5,474.39	20,166.15	15,063.30	21,539.92
	e) Depreciation	493.11	440.30	1,430.63	1,271.52	1,681.65	1,699.76	1,042.42	4,536.95	3,045.54	4,718.52
	f) Other Expenditure	1,405.69	1,303.04	4,806.66	3,854.45	5,510.88	4,691.57	3,496.01	14,232.24	10,038.74	14,161.54
	<b>g) Total</b>	<b>8,169.79</b>	<b>7,647.40</b>	<b>21,678.96</b>	<b>20,382.94</b>	<b>28,395.42</b>	<b>22,722.26</b>	<b>17,721.57</b>	<b>62,735.43</b>	<b>48,360.75</b>	<b>69,739.22</b>
3	<b>Profit from Operations before Other Income, Interest and Exceptional Items (1-2)</b>	<b>2,798.49</b>	<b>2,444.71</b>	<b>9,485.25</b>	<b>5,324.88</b>	<b>7,624.58</b>	<b>5,492.97</b>	<b>2,997.09</b>	<b>14,662.60</b>	<b>7,871.80</b>	<b>10,704.86</b>
4	Other Income	0.01	206.33	591.87	516.36	844.36	0.01	206.33	591.87	516.36	844.36
5	<b>Profit before Interest and Exceptional Items (3+4)</b>	<b>2,798.50</b>	<b>2,651.04</b>	<b>10,077.12</b>	<b>5,841.24</b>	<b>8,468.94</b>	<b>5,492.98</b>	<b>3,203.42</b>	<b>15,254.47</b>	<b>8,388.16</b>	<b>11,549.22</b>
6	Interest & Financial Charges (Net)	460.82	221.24	1,220.55	527.89	721.35	1,009.29	767.14	2,806.51	2,094.72	3,049.83
7	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>2,337.68</b>	<b>2,429.81</b>	<b>8,856.58</b>	<b>5,313.35</b>	<b>7,747.59</b>	<b>4,483.69</b>	<b>2,436.28</b>	<b>12,447.96</b>	<b>6,293.44</b>	<b>8,499.39</b>
8	Exceptional Items	(617.75)	(160.00)	(2,281.08)	312.57	(486.43)	489.33	981.77	(4,254.97)	2,591.57	3,785.68
9	<b>Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)</b>	<b>1,719.93</b>	<b>2,269.81</b>	<b>6,575.50</b>	<b>5,625.92</b>	<b>7,261.16</b>	<b>4,973.02</b>	<b>3,418.05</b>	<b>8,192.99</b>	<b>8,885.01</b>	<b>12,285.07</b>
10	Tax expense	212.86	175.44	458.10	605.96	1,123.05	998.40	219.80	1,148.03	714.58	133.32
	- Current Tax net off MAT	126.39	-	211.78	-	638.89	303.98	35.13	490.15	99.04	673.89
	- Deferred	78.18	167.96	225.99	588.96	459.95	686.12	177.20	637.51	598.20	(565.10)
	- Fringe Benefit	8.30	7.47	20.33	17.00	24.22	8.30	7.47	20.37	17.34	24.53
11	<b>Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)</b>	<b>1,507.07</b>	<b>2,094.37</b>	<b>6,117.40</b>	<b>5,019.96</b>	<b>6,138.11</b>	<b>3,974.62</b>	<b>3,198.25</b>	<b>7,044.96</b>	<b>8,170.43</b>	<b>12,151.75</b>
12	a) Extraordinary Items (net of tax expense Rs.____)	-	-	-	-	-	-	-	-	-	-
	b) Prior Period Expenses	0.06	(7.27)	26.50	(0.23)	9.24	0.21	(7.05)	26.81	0.33	8.03
	c) Short provision of Income Tax	17.39	-	17.39	-	173.06	17.39	-	17.39	-	173.04
13	<b>Net Profit (+)/ Loss (-) for the period (11-12)</b>	<b>1,489.62</b>	<b>2,101.65</b>	<b>6,073.51</b>	<b>5,020.19</b>	<b>5,955.81</b>	<b>3,957.02</b>	<b>3,205.30</b>	<b>7,000.76</b>	<b>8,170.10</b>	<b>11,970.68</b>
14	Paid-up Equity Share Capital (Face Value of Rs 2/- per equity share)	1,613.94	1,550.63	1,613.94	1,550.63	1,593.68	1,613.94	1,550.63	1,613.94	1,550.63	1,593.68
15	Reserves Excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	43,607.26	-	-	-	-	52,641.13
16	Basic and Diluted EPS (before & after Extraordinary Items)										
	Basic EPS (in Rs.Not annualised)	1.85	2.77	7.54	6.81	7.81	4.92	4.22	8.69	6.67	15.70
	Diluted EPS (in Rs.Not annualised)	1.83	2.60	7.47	6.20	7.35	4.87	3.96	8.61	5.29	14.75
17	Public Shareholding										
	- Number of Equity Shares	31,655,667	28,561,290	31,655,667	28,561,290	30,719,063	31,655,667	28,561,290	31,655,667	28,561,290	30,719,063
	- Percentage of Shareholding	39.23	36.84	39.23	36.84	38.55	39.23	36.84	39.23	36.84	38.55

Segment wise Revenue ,Result and Capital Employed

Sr. No	PARTICULARS	3 Months ended	Corresponding 3 months ended in the previous year	Year to Date figures for current Period ended	Year to date figures for the previous period ended	Previous accounting year ended	3 Months ended	Corresponding 3 months ended in the previous year	Year to Date figures for current Period ended	Year to date figures for the previous period ended	Previous accounting year ended
		31-12-2008	31-12-2007	31-12-2008	31-12-2007	31-03-2008	31-12-2008	31-12-2007	31-12-2008	31-12-2007	31-03-2008
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Segment Revenue</b>										
	(a) CRAMS	5,706.31	5,010.91	21,479.06	13,507.72	18,784.82	19,035.61	15,500.11	56,612.78	42,169.68	60,162.09
	(b) Marketable Molecules (MM)	5,244.40	4,137.93	9,636.86	11,241.23	15,250.69	9,160.54	4,291.11	20,372.59	13,077.04	18,261.00
	(c) Others	-	865.98	-	865.98	1,884.52	-	865.98	-	865.98	1,884.53
	<b>Total</b>	<b>10,950.71</b>	<b>10,014.82</b>	<b>31,115.93</b>	<b>25,614.93</b>	<b>35,920.03</b>	<b>28,196.15</b>	<b>20,657.20</b>	<b>76,985.37</b>	<b>56,112.70</b>	<b>80,307.62</b>
	Less: Inter-segment Revenue	-	-	-	-	-	-	-	-	-	-
	<b>Net Sales /Income from Operation</b>	<b>10,950.71</b>	<b>10,014.82</b>	<b>31,115.93</b>	<b>25,614.93</b>	<b>35,920.03</b>	<b>28,196.15</b>	<b>20,657.20</b>	<b>76,985.37</b>	<b>56,112.70</b>	<b>80,307.62</b>
<b>2</b>	<b>Segment Results {(Profit)(+)/(Loss)(-) before tax and interest from each segment}</b>										
	(a) CRAMS*	1,691.01	1,504.74	6,154.72	3,878.61	5,539.97	4,549.39	3,165.92	7,080.03	8,612.36	13,038.71
	(b) Marketable Molecules (MM)*	489.73	634.87	1,049.45	1,613.73	1,294.80	1,432.42	667.83	3,325.54	1,703.69	1,030.92
	(c) Others	-	145.11	-	145.11	303.38	-	145.11	-	147.32	420.91
	<b>Total</b>	<b>2,180.74</b>	<b>2,284.72</b>	<b>7,204.17</b>	<b>5,637.45</b>	<b>7,138.15</b>	<b>5,981.81</b>	<b>3,978.86</b>	<b>10,405.57</b>	<b>10,463.37</b>	<b>14,490.54</b>
	Less: i) Interest	460.82	221.24	1,220.55	527.89	721.35	1,009.29	767.14	2,806.51	2,094.72	3,049.83
	ii) Other un-allocable expenditure net off un-allocable income	(0.01)	(206.33)	(591.87)	(516.36)	(844.36)	(0.50)	(206.33)	(593.93)	(516.36)	(844.36)
	<b>Total Profit Before Tax</b>	<b>1,719.93</b>	<b>2,269.81</b>	<b>6,575.50</b>	<b>5,625.92</b>	<b>7,261.16</b>	<b>4,973.02</b>	<b>3,418.05</b>	<b>8,192.99</b>	<b>8,885.01</b>	<b>12,285.07</b>
<b>3</b>	<b>Capital Employed (Segment Assets-Segment liabilities)</b>										
	(a) CRAMS	26,123.90	11,374.74	26,123.90	11,374.74	20,853.74	33,964.87	20,395.08	33,964.87	20,395.08	33,888.86
	(b) Marketable Molecules (MM)	8,234.84	5,676.38	8,234.84	5,676.38	6,779.06	14,617.20	5,990.86	14,617.20	5,990.86	7,736.83
	(c) Others	20,923.16	26,405.42	20,923.16	26,405.42	20,552.79	21,956.91	29,292.08	21,956.91	29,292.08	18,157.70
	<b>Total</b>	<b>55,281.90</b>	<b>43,456.54</b>	<b>55,281.90</b>	<b>43,456.54</b>	<b>48,185.59</b>	<b>70,538.98</b>	<b>55,678.02</b>	<b>70,538.98</b>	<b>55,678.02</b>	<b>59,783.39</b>
	* Includes Forex (Loss) / Gain										

On behalf of the Board

Sd/  
Janmejy R Vyas  
Managing Director

Place: Ahmedabad  
Date: 29th January, 2009